CD8A and neoplasm: Next, we assessed if the therapy effect of mOVA2 immunization: correlates with the enhanced frequency of SIINFEKL-specific CD8 T cells [compared to poly(I:C) + SIINFEKL; Fig. 5a–c]; and depends on the presence of the OVA antigen in the tumor target.